Premier Alternatives

Ambros Therapeutics

Biotechnology · Irvine, CA · Founded 2024 · Privately Held (backing)

Operator of a therapeutics company intended to address Complex Regional Pain Syndrome Type 1 (CRPS-1). Ambros Therapeutics is based in Irvine, CA and was founded in 2024. It was valued at $250 million at its early-stage round in Dec 2025, the last priced event on record. It has raised $154 million across 1 recorded round; the latest was a $154 million Series A in Dec 2025.

PMV mark · valuation
$250.0M
Oct 2026
Priced at
its early-stage round
Dec 2025
Total raised
$154.0M
Last round
Early Stage VC (Series A)
Dec 2025

Ambros Therapeutics key facts

as of Oct 2026
  • Operator of a therapeutics company intended to address Complex Regional Pain Syndrome Type 1 (CRPS-1).
  • Ambros Therapeutics is valued at approximately $250.0M as of Oct 2026, set at its early-stage round, Dec 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $154.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($154.0M) in Dec 2025.
  • Notable investors include RA Capital Management, Arkin Capital, Adage Capital Management, Balyasny Asset Management, Abiogen Pharma — 9 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$250.0M

Valued at $250.0M at its early-stage round, Dec 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Ambros Therapeutics with a free account
  • ·Watch Ambros Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Ambros Therapeutics funding rounds

1 rounds
Dec 2025Early Stage VC (Series A)$154.0M▮
Full funding history →

Ambros Therapeutics valuation

Ambros Therapeutics was valued at $250 million at its early-stage round in Dec 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Ambros Therapeutics raised?

Ambros Therapeutics has raised $154 million across 1 recorded round since 2025. The largest was a $154 million Series A in Dec 2025.

Ambros Therapeutics investors

9 investors are on record for Ambros Therapeutics, including RA Capital Management, Arkin Capital, Adage Capital Management and Balyasny Asset Management. The Series A in Dec 2025 drew 8 investors.

Comparable companies

Comparable biotechnology names by valuation on PrivateMarketView: Ansa Biotechnologies ($269 million), Gameto ($243 million) and Antheia ($240 million).

About Ambros Therapeutics

Operator of a therapeutics company intended to address Complex Regional Pain Syndrome Type 1 (CRPS-1). The company offers a Phase 3 pivotal trial program of neridronate (a differentiated bisphosphonate) for patients with CRPS-1, enabling clinicians and patients to access a potential treatment where no FDA-approved medicine currently exists for this condition.

Industry
Biotechnology
Sector
Healthcare
HQ
Irvine, CA, United States
Founded
2024
Employees
14
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.